Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Inclusion Criteria

• •Diagnosis of HS for at least 6 months before screening visit.
• •Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
• •Total estimated treatment BSA \> 20% at screening and baseline.
• •Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
• •Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.